76293-13-5

Usage

Uses

Used in Photoinitiation:
2,4-Dimethylthioxanthen-9-one is used as a photoinitiator in the polymer industry for initiating crosslinking or polymerization reactions when exposed to ultraviolet light. Its ability to absorb UV light effectively makes it a key component in the production of various polymer materials.
Used in Inks, Coatings, and Adhesives:
In the printing and packaging industries, 2,4-Dimethylthioxanthen-9-one is used as a component in the formulation of inks, coatings, and adhesives. Its strong UV absorption properties contribute to the performance and quality of these products.
Used in Dye Synthesis:
2,4-Dimethylthioxanthen-9-one is used as a starting material in the synthesis of dyes. Its chemical structure provides a foundation for creating a range of colored compounds.
Used in Pharmaceutical Compounds:
In the pharmaceutical industry, 2,4-Dimethylthioxanthen-9-one is used in the synthesis of various pharmaceutical compounds. Its versatile reactivity and structural properties make it a valuable intermediate in the development of new drugs.
Used in Medicinal Chemistry and Organic Synthesis:
2,4-Dimethylthioxanthen-9-one has potential applications in medicinal chemistry and organic synthesis due to its versatile reactivity and structural properties. It serves as a building block for the creation of new compounds with potential therapeutic applications.

InChI:InChI=1/C15H12OS/c1-9-7-10(2)15-12(8-9)14(16)11-5-3-4-6-13(11)17-15/h3-8H,1-2H3

Upstream product

• 119-80-2 2,2'-dithiobenzoic acid 
• 108-38-3 m-xylene 
• 147-93-3 Thiosalicylic acid 
• 113296-91-6 2-(2,4-dimethylphenylthio)benzoic acid 
• 13616-82-5 2,4-dimethyl-thiophenol 
• 118-91-2 ortho-chlorobenzoic acid 
• 108-88-3 toluene 

Downstream Products

• 73839-38-0 2,4,9-trimethyl-9-(N-p-toluenesulfonamido)thioxanthene 
• 73839-33-5 trans-2,4,9-trimethylthioxanthene N-(p-toluenesulfonyl)sulfilimine 

Relevant academic research and scientific papers

Novel thioxanthone compound synthesis method

The invention belongs to the technical field of synthesis and discloses a novel thioxanthone compound synthesis method. The method includes steps: sequentially adding alkali and o-chlorobenzoic acid into a solvent, stirring to enable neutralization reaction, dropwise adding alkyl thiophenol into a reaction system after heat release stops in neutralization reaction, heating to 120-220 DEG C, keeping the temperature, and performing etherification reaction for 8-12h; after etherification reaction is finished, cooling to the room temperature, starting tail gas absorption, keeping the pressure of the reaction system in a range from -0.03 to -0.08Mpa, dropwise adding concentrated sulfuric acid into etherified liquid, performing thermal reaction at 20-60 DEG C for 3-7h, and dropwise adding a dehydrating agent into the reaction system in the reaction process to remove water generated in cyclization reaction; adding water into reaction liquid after reaction, stirring, standing for layering, andsubjecting organic supernatant to solvent removal and recrystallization to obtain a target product namely a thioxanthone compound. The total product yield is high, sulfuric acid solution containing potassium hydrogen sulfate is a byproduct, and easiness in treatment and recovery and environmental friendliness are realized.

Methods of treating conditions associated with an Edg-7 receptor

In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.

Methods of treating conditions associated with an Edg-7 receptor

In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.

O-acyloxime photoinitiators

Oximeester compounds of the formulae I, II, III and IV whereinR1 is phenyl, C1-C20alkyl or C2-C20alkyl optionally interrupted by —O—, C2-C20alkanoyl or benzoyl, or R1 is C2-C12alkoxycarbonyl or phenoxycarbonyl; R1′ is C2-C12alkoxycarbonyl, or R1′ is phenoxycarbonyl, or R1′ is —CONR10R11 or CN; R2 is C2-C12alkanoyl, C4-C6alkenoyl, benzoyl, C2-C6alkoxycarbonyl or phenoxycarbonyl; R3, R4, R5, R6 and R7 are hydrogen, halogen, C1-C12alkyl, cyclopentyl, cyclohexyl, phenyl, benzyl, benzoyl, C2-C12alkanoyl, C2-C12alkoxycarbonyl, phenoxycarbonyl or a group OR8, SR9, SOR9, SO2R9 or NR10R11; R4′, R5′ and R6′ are hydrogen, halogen, C1-C12alkyl, cyclopentyl, cyclohexyl, phenyl, benzyl, benzoyl, C2-C12-alkanoyl, C2-C12alkoxycarbonyl, phenoxycarbonyl, or are a group OR8, SR9, SOR9, SO2R9, NR10R11; provided that at least one of R3, R4, R5, R6, R7, R′4, R′5 and R′6 is OR8, SR9 or NR10R11; R8, R9, R10 and R11 are for example hydrogen, C1-C12alkyl, phenyl; are suitable as initiators for the photopolymerization of radically polymerizable compounds.